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1. INTRODUCTION {#jmv26402-sec-0010}
===============

Currently, the world is trampled by the coronavirus disease 2019 (COVID‐19) with more than 18 million cases and 695 129 deaths already reported (till 8th August 2020). Due to the novelty of COVID‐19 disease, there is an ongoing effort by basic science researchers and clinicians worldwide to learn more about this disease. Complement activation, immune dysregulation, and coagulation cascade perturbations have been studied as the most potential pathophysiological mechanisms for COVID‐19 disease.[^1^](#jmv26402-bib-0001){ref-type="ref"} Recent reports of immune effects of COVID‐19, such as immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA), suggest the pathological interaction between coronavirus (severe acute respiratory syndrome coronavirus 2 \[SARS‐CoV‐2\]) and various immune and tissue cells of our body. We hereby aim to summarize the collection of reported cases of ITP and AIHA secondary to COVID‐19 reported to date.[^2^](#jmv26402-bib-0002){ref-type="ref"}, [^3^](#jmv26402-bib-0003){ref-type="ref"}, [^4^](#jmv26402-bib-0004){ref-type="ref"}, [^5^](#jmv26402-bib-0005){ref-type="ref"}, [^6^](#jmv26402-bib-0006){ref-type="ref"}, [^7^](#jmv26402-bib-0007){ref-type="ref"}, [^8^](#jmv26402-bib-0008){ref-type="ref"}, [^9^](#jmv26402-bib-0009){ref-type="ref"}, [^10^](#jmv26402-bib-0010){ref-type="ref"}

2. METHODOLOGY AND RESULTS {#jmv26402-sec-0020}
==========================

In our literature search, we found 20 patients with COVID‐19 who were reported to have immune dysregulation with the development of ITP, AIHA, and/or Evan\'s syndrome. In total, there were 10 (50%) patients with ITP, 9 (45%) patients with AIHA, and 1 (5%) patient had Evan\'s syndrome. The average age of the patients was 61 (17‐89 years) years with the majority (55%) being males (11 out of 20). Four out of 20 (20%) patients also had a previous history of autoimmune disease (one each with polymyalgia rheumatica and autoimmune hypothyroidism, and two with chronic ITP). To note, one (5%) patient also had congenital thrombocytopenia.[^11^](#jmv26402-bib-0011){ref-type="ref"} Regarding the underlying malignancies, eight (40%) patients were found to have history of cancers, six with lymphoproliferative disorders (CLL‐2, MZL‐2, MGUS‐1, and ALPS‐1) and the remaining two with solid malignancies. The largest case series of AIHA with COVID‐19 (7 cases) to date has been reported by Lazarian et al.

Our review showed that most patients who had bleeding symptoms only reported of superficial bruising, petechial spots, or hemorrhages. Only 2 patients out of 20 (10%) suffered from intracranial bleeding, one out of which died. Reported nadir platelet counts in ITP cases were extremely variable with as high as 338 000 cells/μL to as low as 0 cell/μL. Similarly, the lowest reported hemoglobin (2.5 gm/dL) in AIHA with COVID‐19 was reported by Wahlster et al.[^12^](#jmv26402-bib-0012){ref-type="ref"} All patients were laboratory‐confirmed COVID‐19 positive with a positive nasopharyngeal swab. With regard to the management, drugs attempted were steroids (dexamethasone, methylprednisone, and prednisone), intravenous immunoglobulin (IVIG), eltrombopag, and rituximab (Table [1](#jmv26402-tbl-0001){ref-type="table"}). Most of the patients (four out of seven) with AIHA reported by Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"} were receiving treatment at the time of publication. Two patients had a partial response and one patient failed to respond to steroids. All nine patients (100%) with AIHA and 9 of 10 patients (90%) with ITP recovered from the acute crisis and were discharged.

###### 

Reported cases of ITP and AIHA in association with COVID‐19

  Author et al                                               Age   Sex      Previous comorbidities                                                                Underlying malignancy             Diagnosis                      Symptoms                                                                                         Bleeding signs/sites                                                                   Zenith WBC, cells/µL   Lymphocyte count, 10^9^/L   Nadir Hb, g/dL   Nadir platelet count, cells/µL   Reticulocyte count, 10^9^/L   LDH             Other laboratory workup                                                                                                                                  Chest imaging                                                                                                               ITP/Evans\'s treatment
  ---------------------------------------------------------- ----- -------- ------------------------------------------------------------------------------------- --------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ---------------------- --------------------------- ---------------- -------------------------------- ----------------------------- --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------
  Li et al[^13^](#jmv26402-bib-0013){ref-type="ref"}         39    Male     None                                                                                  None                              Evan\'s syndrome (new onset)   Hemoptysis and epistaxis ×1 d, sore throat, productive cough, fevers, chills, and dyspnea ×7 d   Oropharynx, nares, and mouth                                                           11 000                                             15.6             3000                             NA                            947             Hemolytic panel negative, no schistocytes                                                                                                                Normal                                                                                                                      IVIG
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   61    Male     HTN, CRF                                                                              Chronic lymphocytic leukemia      AIHA (warm type)               NM                                                                                               NM                                                                                     NM                     250                         6                NM                               477                           1000            Coombs test positive (IgG + C3d)                                                                                                                         Moderate                                                                                                                    Steroids
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   89    Female   HTN, CRF, AFIB                                                                        MGUS                              AIHA (warm type)               NM                                                                                               NM                                                                                     NM                     1.7                         8.4              NM                               103                           598             Coombs test positive (IgG + C3d)                                                                                                                         Mild                                                                                                                        Steroids
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   62    Female   HTN, cirrhosis                                                                        MZL                               AIHA (cold type)               NM                                                                                               NM                                                                                     NM                     1.3                         10.8             NM                               101                           357             Coombs test positive (C3d)                                                                                                                               Severe                                                                                                                      Steroids, rituximab
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   69    Female   Obesity, HTN                                                                          MZL                               AIHA (cold type)               NM                                                                                               NM                                                                                     NM                     5.9                         3.8              NM                               215                           2610            Coombs test positive (IgG + C3d)                                                                                                                         Moderate                                                                                                                    Steroids
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   61    Male     CRF, HLD, type 2 DM                                                                   Prostate cancer                   AIHA (cold type)               NM                                                                                               NM                                                                                     NM                     3                           7.2              NM                               145                           807             Coombs test positive (C3d)                                                                                                                               Mild                                                                                                                        RBC infusion
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   61    Male     Type 2 DM, HLD                                                                        None                              AIHA (warm type)               NM                                                                                               NM                                                                                     NM                     1.2                         7                NM                               155                           1800            Coombs test positive (IgG)                                                                                                                               Severe                                                                                                                      Steroids, rituximab
  Lazarian et al[^10^](#jmv26402-bib-0010){ref-type="ref"}   75    Male     Cardiomyopathy, obesity, COPD                                                         CLL                               AIHA (warm type)               NM                                                                                               NM                                                                                     NM                     108                         7.1              NM                               98                            2000            Coombs test positive (IgG)                                                                                                                               Moderate                                                                                                                    RBC infusion
  Bomhof et al[^3^](#jmv26402-bib-0003){ref-type="ref"}      59    Male     NA                                                                                    Stage IV NET of the small bowel   New onset ITP                  Coughing and fever 10 d, contact with a positive case                                            Oral mucosal petechiae and spontaneous skin hematomas                                  3900                   400                         8.3              3000                             NM                            Not mentioned   Platelet autoantibodies positive for GP1b, GPIIBIIa, and GPV. Viral serology for HIV, Hepatitis B and C, EBV, Parvo B19 virus, CMV virus were negative   NM                                                                                                                          SDAP, IVIG, dexamethasone
  Bomhof et al[^3^](#jmv26402-bib-0003){ref-type="ref"}      66    Female   HTN                                                                                                                     New onset ITP                  Fever, dyspnea, and coughing during a week, followed by diarrhea and vomiting for several days   Petechiae, spontaneous epistaxis, and increased blood loss from hemorrhoids for 3 wk   5800                   700                         8                2000                             NM                            NM              Platelet autoantibodies negative. Viral serology for HIV, hepatitis B and C, EBV were negative                                                           NM                                                                                                                          Dexamethasone, IVIG
  Bomhof et al[^3^](#jmv26402-bib-0003){ref-type="ref"}      67    Male     HTN, type 2 DM                                                                                                          ITP                            Fever, coughing, and dyspnea ×9 d                                                                                                                                                       11 200                 860                         9.3              338 000                          NM                            NM              Platelet autoantibodies testing and viral serology testing not done                                                                                      Bilateral infiltrates                                                                                                       
  Lopez et al[^11^](#jmv26402-bib-0011){ref-type="ref"}      46    Female   Congenital thrombocytopenia                                                           None                              AIHA (warm)                    Dyspnea and cough                                                                                None                                                                                   9850                   680                         9.7              43 000                           206                           553             Coombs test positive (IgG + C3d), ANA was negative                                                                                                       Dense left upper lobe consolidation with minimal surrounding ground‐glass opacities and no evidence of pulmonary embolism   IVIG
  Tang et al[^8^](#jmv26402-bib-0008){ref-type="ref"}        NA    Female   41 wk pregnant woman                                                                  None                              New onset ITP                  Sore throat                                                                                      No bleeding                                                                            NM                     NM                          NM               16 000                           NM                            NM              Monoclonal antibody immobilization of platelet antigens (MAIPA) showed platelet autoantibodies against glycoprotein V                                    Left lower lobe with ground‐glass opacities                                                                                 IVIG, platelet transfusion
  Zulfiqar et al[^9^](#jmv26402-bib-0009){ref-type="ref"}    65    Female   HTN, autoimmune hypothyroidism                                                        None                              New onset ITP                  Fatigue, fever, dry cough, and abdominal discomfort of 4 d                                       Lower‐extremity purpura, subarachnoid microhemorrhage                                  Normal                 NM                          14.2             1000                             NM                            NM              Antiplatelet antibodies and antinuclear antibodies were not detected                                                                                     Ground‐glass opacities in the lower zones                                                                                   IVIG, prednisone, eltrombopag
  Hu et al[^5^](#jmv26402-bib-0005){ref-type="ref"}          72    Female   Chronic ITP (in remission with prednisone \[10 mg/d\] and cyclosporine \[50 mg/d\])   None                              Relapse of chronic ITP         Productive cough ×4 d and fever ×1 d                                                             None                                                                                   None                   2550                        NM               18 000                           NM                            LDH             None                                                                                                                                                     Peripheral ground‐glass opacity in the right lower lobe                                                                     IVIG, platelet transfusion, methylprednisolone
  Murt et al[^7^](#jmv26402-bib-0007){ref-type="ref"}        41    Male     None                                                                                  None                              New onset ITP                  Cough and runny nose 15 d ago                                                                    Petechiae and nasal bleeding                                                                                                                               9000                                                                           NM                                                                                                                                                       Bilateral ground‐glass opacities                                                                                            High‐dose dexamethasone, IVIG
  Humbert et al[^6^](#jmv26402-bib-0006){ref-type="ref"}     84    Male     Polymyalgia rheumatica, essential tremor                                              None                              New onset ITP                  Cough and progressive dyspnea ×10 d                                                              Spontaneous macroscopic hematuria and bilateral epistaxis                              9200                   330                         12.2             4000                             NM                            NM              ANA negative, platelet antibodies negative, lupus anticoagulant antibody                                                                                 Diffuse ground‐glass opacities and condensations involving more than 50% of pulmonary parenchyma                            Prednisone, IVIG
  Wahlster et al[^12^](#jmv26402-bib-0012){ref-type="ref"}   17    Male     Chronic ITP (in remission with eltrombopag and mycophenolate)                         ALPS                              AIHA                           Worsening jaundice and fatigue in the setting of 4 d of emesis, diarrhea, and fevers             None                                                                                   4370                   440                         2.5              94 000                           NM                            1280            IgG 3+, C3 1+                                                                                                                                            Mild prominence of perihilar markings                                                                                       Steroids
  Ahmed et al[^2^](#jmv26402-bib-0002){ref-type="ref"}       50    Male     None                                                                                  None                              New onset ITP                  Asymptomatic, close contact with COVID‐19 positive                                               Epistaxis, oral blisters, and a generalized petechial rash                             4000                   NM                          13.2             Not detected                     NM                            NM              NM                                                                                                                                                       Normal                                                                                                                      IVIG, tranexamic acid
  Ahmed et al[^2^](#jmv26402-bib-0002){ref-type="ref"}       49    Female   None                                                                                  None                              New onset ITP                  Asymptomatic, close contact with COVID‐19 positive                                               Generalized bruises and gum bleed                                                      5300                   None                        13.4             4000                             NM                            NM              Negative                                                                                                                                                 Revealed bilateral patchy consolidation                                                                                     IVIG

Abbreviations: AFIB, atrial fibrillation; AIHA, autoimmune hemolytic anemia; ALPS, autoimmune lymphoproliferative syndrome; ANA, antinuclear antibody; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease 2019; CRF, cardiorespiratory fitness; EBV, Epstein‐Barr virus; Hb, hemoglobin; HIV, human immunodeficiency; HLD, hyperlipidemia; HTN, hypertension; ITP, immune thrombocytopenia; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; MGUS, monoclonal gammopathy of undetermined significance; MZL, marginal zone lymphoma; NA, not applicable; NET, neuroendocrine tumor; NM, not mentioned; Parvo B19, parvovirus B19; RBC, red blood cell; type 2 DM, type 2 diabetes mellitus; WBC, white blood cell.
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3. DISCUSSION {#jmv26402-sec-0030}
=============

Thrombocytopenia is one of the challenging disease entities faced by clinicians in day‐to‐day clinical practice.[^14^](#jmv26402-bib-0014){ref-type="ref"}, [^15^](#jmv26402-bib-0015){ref-type="ref"} Immune‐mediated hematologic conditions, characterized by ITP, AIHA, or Evan\'s syndrome, are known to be associated with previous exposure to various viral infections. Platelet‐virus interplay could represent a combination of multiple pathways that may include complement activation, antigen mimicry of platelet surface glycoproteins, consumptive coagulopathy, and direct bone marrow suppression.[^16^](#jmv26402-bib-0016){ref-type="ref"} Similarly, AIHA is a common association with indolent lymphoproliferative disorders, and the coinfection of SARS‐CoV‐2 could potentially trigger hemolysis (Figure [1](#jmv26402-fig-0001){ref-type="fig"}). Treatment of autoimmune disorders is always challenging in the presence of active infection. Hematologists and other physicians often prefer IVIG as an initial therapy when the concerns of worsening of active infection or risk of acquiring a superadded infection are high.[^17^](#jmv26402-bib-0017){ref-type="ref"}, [^18^](#jmv26402-bib-0018){ref-type="ref"} Due to concerns that steroids may worsen the SARS‐CoV‐2 infection and could lead to acute respiratory distress syndrome, World Health Organization (WHO) recommends against using steroids in COVID‐19.[^16^](#jmv26402-bib-0016){ref-type="ref"} In the present patient cohort, most of the patients received steroids for their autoimmune disease and not COVID‐19.

![Mechanisms of SARS‐CoV‐2 induced thrombocytopenia. SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2](JMV-9999-na-g001){#jmv26402-fig-0001}

4. CONCLUSION {#jmv26402-sec-0040}
=============

In conclusion, hematological findings such as thrombocytopenia and anemia in COVID‐19 could be due to multiple reasons and timely diagnosis of the immunological cause is essential, so that appropriate immunosuppression can be initiated in a timely fashion.
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